Novo Nordisk NovoFine 32G Tip Needle Singapore - engleză - HSA (Health Sciences Authority)

novo nordisk novofine 32g tip needle

novo nordisk pharma (singapore) pte ltd - general hospital - it is intended for use with disposable and durable drug delivery systems by novo nordisk.

LEVEMIR Israel - engleză - Ministry of Health

levemir

novo nordisk ltd., israel - insulin detemir - solution for injection - insulin detemir 100 u/ml - insulin detemir - treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.

NOVORAPID Israel - engleză - Ministry of Health

novorapid

novo nordisk ltd., israel - insulin aspart - solution for injection - insulin aspart 100 u/ml - insulin aspart - treatment of patients with diabetes mellitus in adults, adolescents and children aged 2 years and above.

NOVORAPID FLEXPEN INJECTION 100 uml Singapore - engleză - HSA (Health Sciences Authority)

novorapid flexpen injection 100 uml

novo nordisk pharma (singapore) pte ltd - insulin aspart - injection - 100 u/ml - insulin aspart 100 u/ml

NOVOSEVEN RT eptacog alfa (activated) (bhk) 8mg powder for injection vial with pre-filled diluent syringe Australia - engleză - Department of Health (Therapeutic Goods Administration)

novoseven rt eptacog alfa (activated) (bhk) 8mg powder for injection vial with pre-filled diluent syringe

novo nordisk pharmaceuticals pty ltd - histidine, quantity: 12.57 mg - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - novoseven rt is indicated for the control of bleeding and surgical prophylaxis in patients: with inhibitors to coagulation factors viii or ix; with congenital fvii deficiency; with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

NOVOSEVEN RT eptacog alfa (activated) (bhk) 5mg powder for injection vial with pre-filled diluent syringe Australia - engleză - Department of Health (Therapeutic Goods Administration)

novoseven rt eptacog alfa (activated) (bhk) 5mg powder for injection vial with pre-filled diluent syringe

novo nordisk pharmaceuticals pty ltd - histidine, quantity: 8.01 mg - injection - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - novoseven rt is indicated for the control of bleeding and surgical prophylaxis in patients: with inhibitors to coagulation factors viii or ix; with congenital fvii deficiency; with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

NOVOSEVEN RT eptacog alfa (activated) (bhk) 2mg powder for injection vial with pre-filled diluent syringe Australia - engleză - Department of Health (Therapeutic Goods Administration)

novoseven rt eptacog alfa (activated) (bhk) 2mg powder for injection vial with pre-filled diluent syringe

novo nordisk pharmaceuticals pty ltd - histidine, quantity: 3.26 mg - injection - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - novoseven rt is indicated for the control of bleeding and surgical prophylaxis in patients: with inhibitors to coagulation factors viii or ix; with congenital fvii deficiency; with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

NOVOSEVEN RT eptacog alfa (activated) (bhk) 1mg powder for injection vial with pre-filled diluent syringe Australia - engleză - Department of Health (Therapeutic Goods Administration)

novoseven rt eptacog alfa (activated) (bhk) 1mg powder for injection vial with pre-filled diluent syringe

novo nordisk pharmaceuticals pty ltd - histidine, quantity: 1.74 mg - injection - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - novoseven rt is indicated for the control of bleeding and surgical prophylaxis in patients with: inhibitors to coagulation factors viii or ix; with congenital fvii deficiency; with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.